Scarica l'app Stockscreener
1.78
2.73%
-0.05
Precedente Chiudi:
$1.83
Aprire:
$1.79
Volume 24 ore:
77,201
Relative Volume:
0.04
Capitalizzazione di mercato:
$22.45M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.18%
1M Prestazione:
-19.82%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.76
$1.82
Intervallo di 1 settimana:
$1.71
$1.97
Portata 52W:
$1.60
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
Nome
Propanc Biopharma Inc
Settore
Industria
Telefono
61-03-9882-0780
Indirizzo
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Confronta PPCB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
4.07 | 5.67B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.22 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.13 | 109.81M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.195 | 429.79M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.08 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Borsa (PPCB) Ultime notizie
Propanc Biopharma Enters Securities Purchase Agreement - TipRanks
Propanc Biopharma enters agreement for Series C preferred stock private placement - Investing.com
Propanc Biopharma receives certificate of grant from USPTO - MSN
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma (OTCMKTS:PPCB) Stock Price Down 2.6% – Time to Sell? - Defense World
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development and $100M+ Digital Asset Treasury Strategy - MarketScreener
Propanc Biopharma reports major financial turnaround after Nasdaq uplisting By Investing.com - Investing.com Nigeria
Propanc Biopharma reports major financial transformation after Nasdaq listing - Investing.com
Propanc reports $100 million digital asset treasury plan, NASDAQ listing By Investing.com - Investing.com Nigeria
Propanc Biopharma plans $100M digital asset treasury strategy By Investing.com - Investing.com Australia
Propanc Biopharma reports total assets of $19.6M as of June 30 - TipRanks
Propanc Biopharma reports major financial turnaround after Nasdaq uplisting - Investing.com India
Propanc Biopharma reports major financial transformation after Nasdaq listing By Investing.com - Investing.com Australia
Propanc reports $100 million digital asset treasury plan, NASDAQ listing - Investing.com India
Propanc Biopharma plans $100M digital asset treasury strategy - Investing.com
Propanc Reports End of Fiscal Year Highlights and Outlines - GlobeNewswire
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy - MarketScreener
$100M+ Digital Treasury Plan: Propanc Pursues Crypto Strategy After Nasdaq Uplisting and $19.6M Assets - Stock Titan
From Lab Bench to Blockchain: How Biotech is Reinventing Funding - The Globe and Mail
Does Propanc Biopharma (NASDAQ:PPCB) Have A Healthy Balance Sheet? - simplywall.st
Propanc Biopharma, Inc. SEC 10-K Report - TradingView
Propanc Biopharma prices $4M stock offering - MSN
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads - The Globe and Mail
Reviewing Immatics (NASDAQ:IMTX) & Propanc Biopharma (OTCMKTS:PPCB) - Defense World
Propanc receives US patent for proenzyme cancer treatment composition By Investing.com - Investing.com South Africa
Propanc receives US patent for proenzyme cancer treatment composition - Investing.com
Propanc Biopharma Receives Certificate of Grant for 'Proenzyme Composition” Patent from US Patent & Trademark Office - The Manila Times
Propanc Biopharma Receives Certificate of Grant for - GlobeNewswire
$111.2B Market Opportunity: Propanc's Non-Toxic Cancer Drug PRP Receives Critical USPTO Patent - Stock Titan
Propanc Biopharma announces plan to acquire $100 million of Ethereum - MSN
Propanc to acquire $100M of Ethereum to accelerate pipeline - BioWorld MedTech
Propanc Biopharma’s $100M Ethereum Allocation: A Strategic Gamble or a Path to Growth? - AInvest
Propanc Biopharma, Inc. Announces $100 Million Ethereum Acquisition Plan to Enhance Growth and Diversification Strategy - Quiver Quantitative
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum - The Manila Times
$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy - Stock Titan
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Stem Cell Research - citybuzz -
D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq - AInvest
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Newswire.com
Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials - Investing.com
Propanc Biopharma shares fall 3.26% after-hours following shareholder update on corporate developments and Phase 1B study. - AInvest
Propanc Biopharma provides shareholder update - MarketScreener
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 By Investing.com - Investing.com South Africa
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 - Investing.com Nigeria
Propanc Biopharma Provides Shareholder Update - The Manila Times
Propanc Biopharma Announces Shareholder Update and 2025/26 Forecast. - AInvest
Propanc Biopharma: Recent IPO and Up-listing to Nasdaq, Advancing Lead Asset to Phase 1B Study - AInvest
Propanc Biopharma Inc Azioni (PPCB) Dati Finanziari
Non sono disponibili dati finanziari per Propanc Biopharma Inc (PPCB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
5.15%
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):